Every year, venomous snake bites claim up to 140,000 lives worldwide, primarily affecting rural areas in Asia and Africa. Current antivenoms typically target only one species or a small group of related species. However, a remarkable story is emerging that could change the landscape of snakebite treatment.
Tim Friede’s Journey: 856 Snake Venom Doses
Tim Friede, a mechanic and snake collector from Wisconsin, embarked on a unique journey in 2001. After acquiring a copperhead snake, he began injecting himself with venom to develop immunity against bites from his own collection. Over 18 years, he administered venom to himself 856 times, either through injection or direct bites.
Friede exposed himself to some of the deadliest snake species, including:
- Black mamba
- Spitting cobra
- Death adder
- Coastal taipan
His extraordinary case drew the attention of immunologist Jacob Glanville, founder of California-based biotechnology firm Centivax. Upon analyzing Friede’s blood, Glanville identified antibodies capable of neutralizing multiple types of venom simultaneously.
Advancements in Antivenom Development
Friede later joined Centivax as the director of herpetology, turning his self-taught experience into a scientific collaboration. The Centivax team isolated two promising antibodies from Friede’s blood. They combined these antibodies with varespladib, an anti-inflammatory agent that blocks specific toxins, and conducted tests on mice.
A study published in the journal Cell in May 2025 revealed that this combination fully protected the mice from fatal doses of venom from 13 different snake species. Additionally, the mixture provided partial protection against six more species. This outcome marks a significant advancement in antivenom research.
The Potential of Universal Antivenom
Traditional antivenoms, derived from horse serum, typically target only one species or closely related families. Moreover, their production is costly and requires consistent access to fresh venom. In contrast, a universal antivenom based on human antibodies could be produced via biotechnology, making it easier to stock and distribute in remote areas.
While these results are promising, they remain preliminary. So far, only mice have been tested, and several years of clinical trials will be essential before any human application. The diversity of toxins in snake venoms poses a significant challenge, as each species has a unique molecular cocktail. The research team emphasized that Friede’s self-exposure should not be replicated due to the life-threatening risks involved.
Nonetheless, this innovative approach presents a tangible opportunity. A single effective treatment for the majority of snakebites would greatly simplify care in rural clinics, where identifying the responsible species is often impossible. If clinical trials confirm these promising results, antivenom derived from Tim Friede’s blood could become the first broad-spectrum treatment against snakebites.
